Drug Profile

CK 0803

Alternative Names: CK-0803

Latest Information Update: 29 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cellenkos
Class Antiparkinsonians; T lymphocyte cell therapies
Mechanism of Action Regulatory T-lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Amyotrophic lateral sclerosis
New Molecular Entity No

Highest Development Phases

Phase I Amyotrophic lateral sclerosis
Preclinical Parkinson's disease
No development reported Chronic inflammatory demyelinating polyradiculoneuropathy

Most Recent Events

20 Oct 2025 CK 0803 receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
20 Oct 2025 Preliminary efficacy and adverse event data from the phase Ib REGALS trial in Amyotrophic lateral sclerosis released by Cellenkos
20 Oct 2025 Cellenkos plans a randomized placebo control trial in 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com